PhysioCue at the American Diabetes Association’s 22nd Annual Leaders Forum HealthTech Showcase

Hypertension reduction therapy technology and device developer PhysioCue, Inc, presented and demonstrated their revolutionary 2.0 Hypertension Reduction Therapy and BP Monitoring Devices at ADA’s HealthTech Showcase in San Mateo on November 3. 


PhysioCue has developed patented and patent-pending hypertension and BP monitoring devices that immediately and sustainably lower—and monitor--blood pressure in most hypertensive patients. This BP reduction is achieved by daily 5-minute therapy applications that gradually condition the patient’s nervous system. Over 30 to 45 days, a BP reduction of 15 to 30 mmHg (systolic and diastolic) is achieved and maintained.

PhysioCue founder and CEO Simon Yi said, "Our enhanced-functioning 2.0 therapy devices provide immediate and safe cold-tip and micro-vibration therapy, and have our embedded, patent-pending PPG/ECG BP biosensor that records the user's blood pressure, before and after therapy, from just two fingers - No more Blood Pressure cuffs!”

The BP data is automatically recorded by the device, for up to 90 days, and is transmitted, via the PhysioCue mobile app, to the cloud, for dissemination to the patient's physician and family members.   


The HealthTech Showcase featured start-up ventures in the life science and digital health arenas and was an opportunity to network with more than 400 Bay Area biotech, private equity and venture capital investors.


PhysioCue, Inc. is a privately held company located in the heart of Silicon Valley.